Human Papillomavirus Genotypes Distribution in High-Grade Cervical Lesions and Invasive Cervical Carcinoma in Women Living in Mauritania: Implications for Cervical Cancer Prevention and HPV Prophylactic Vaccination
Authors:
- Mariem Salma AbdoudaimMAMariem Salma Abdoudaim
- Mohamed Val Mohamed AbdellahiMAMohamed Val Mohamed Abdellahi
- Nacer Dine Mohamed BabaNBNacer Dine Mohamed Baba
- Ralph-Sydney Mboumba BouassaRBRalph-Sydney Mboumba Bouassa
- Mohamed Lemine Cheikh Brahim AhmedMohamed Lemine Cheikh Brahim Ahmed
- Laurent BélecLBLaurent Bélec
Open Access
- 8 September 2024
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 14 (17) , 1986
Abstract
Cervical cancer related to high-risk human papillomavirus (HR-HPV) is the second female cancer in Mauritania (Northwest Sahelian Africa). We assessed the distribution of HPV genotypes in Mauritanian women with high-grade cervical intraepithelial neoplasia (CIN2/3) or invasive cervical cancer (ICC). A prospective study was conducted in the Centre Hospitalier National, Nouakchott, Mauritania, to collect cervical biopsies among women suspected of CIN2/3 or cancer. HPV DNA detection and genotyping were carried out from formalin-fixed, paraffin-embedded biopsies using multiplex PCR (Human Papillomavirus Genotyping Real-Time PCR Kit, Bioperfectus Technologies Co., Taizhou, China). Fifty biopsies were included from women (mean age: 56.7 years) suffering from CIN2/3 (28.0%) and ICC (72.0%) which corresponded to 32 (64.0%) squamous cell carcinomas (SCC) and 4 (8.0%) adenocarcinomas (ADC). HPV DNA detection was successful in 47 (94.0%) samples. The most prevalent HR-HPV genotypes were HPV-45 (40.4%), HPV-16 (38.3%), HPV-39 and HPV-52 (23.4%), HPV-33 (17.0%), HPV-18 (14.9%), HPV-35 (4.2%), and HPV-56 (2.1%). The majority (93.6%) of HPV-positive biopsies contained at least one HPV type covered by the 9-valent Gardasil-9® vaccine, and 40.9% were infected by multiple vaccine HPV genotypes. To eradicate cervical cancer in Mauritania, prophylactic HPV vaccination must be combined with primary molecular screening of cervical HR-HPV infection.Keywords
This publication has 72 references indexed in Scilit:
- Academic accountability to local communities and society through Programme Science: a case study from the HPV self‐sampling programme HOPE in PeruJournal of the International AIDS Society, 2024
- Evaluation of a novel vaginal cells self‐sampling device for human papillomavirus testing in cervical cancer screening: A clinical trial assessing reliability and acceptabilityBioengineering & Translational Medicine, 2024
- Respective prevalence of high‐risk HPVgenotypes in cervical neoplasia in SenegalJournal of Medical Virology, 2021
- Worldwide burden of cancer attributable to HPV by site, country and HPV typeInternational Journal of Cancer, 2017
- Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub‐Saharan AfricaInternational Journal of Cancer, 2013
- Human papillomavirus infection in women in four regions of SenegalJournal of Medical Virology, 2013
- Genotyping of human papillomavirus in paraffin embedded cervical tissue samples from women in ethiopia and the SudanJournal of Medical Virology, 2012
- Human papillomavirus type 52 polymorphism and high‐grade lesions of the uterine cervixInternational Journal of Cancer, 2012
- Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publicationInternational Journal of Cancer, 2010
- Cervical infections by multiple human papillomavirus (HPV) genotypes: Prevalence and impact on the risk of precancerous epithelial lesionsJournal of Medical Virology, 2009